Full-Time

Senior Financial Analyst

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$138k - $172kAnnually

Senior

San Carlos, CA, USA

Position based out of headquarters in Redwood City, CA.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
NetSuite
Financial analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor's degree in finance, Accounting, or related field.
  • Biotech or Big 4 Accounting experience.
  • Highly proficient in Excel and strong attention to detail.
  • Prior ERP and financial systems experience: Sage Intaact, Netsuite, etc.
  • Strong work ethic and ability to adjust workload based on changing priorities.
  • Excellent written and verbal communications.
Responsibilities
  • Prepare month-end clinical trial accruals, including review of CRO reports, patient costs, and site payments.
  • Prepare monthly and quarterly reconciliations for accrued clinical and related prepaid accounts.
  • Review contracts and amendments to analyze and determine impact on clinical accruals.
  • Work with external CROs and vendors to ensure that expenses are accurately accounted for.
  • Ensure and maintain proper documentation and internal controls around clinical trial accruals for SOX compliance.
  • Partner with accounting team to support monthly and quarterly close activities.
  • Support the annual audit and quarterly reviews through preparation of audit schedules and other documentation as requested by external auditors.
  • Help with variance analysis of actuals to budget, explain, and investigate any major discrepancies, and understand key business drivers.
  • Review Purchase Order requests.
  • Prepare ad hoc financial analysis and analytical support as needed.
Desired Qualifications
  • CPA or MBA.
  • Minimum 3-5 years’ experience in Big 4 or biotechnology industry.
  • Strongly prefer experience in reviewing clinical contracts (i.e. CRO contracts, Site contracts, protocols, etc.).
  • Prior experience with clinical trial accruals.
  • Adaptive Planning (Office Connect) experience a plus.
  • Coupa experience a plus.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to inhibit the activity of RAS proteins that promote cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity